<DOC>
	<DOC>NCT01039194</DOC>
	<brief_summary>The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.</brief_summary>
	<brief_title>Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Healthy men and postmenopausal women Gastrointestinal disorders Bleeding disorders Peptic ulcer disease Cholecystectomy Seizure disorder Asthma Chronic obstructive pulmonary disease Urinary tract obstruction Cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes Inability to tolerate oral medication Inability to be venipunctured and/or tolerate venous access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>